Advertisement
UK markets closed
  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     
  • FTSE 250

    20,786.65
    +176.31 (+0.86%)
     
  • AIM

    774.39
    +4.97 (+0.65%)
     
  • GBP/EUR

    1.1819
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2813
    +0.0052 (+0.41%)
     
  • Bitcoin GBP

    45,092.91
    +776.87 (+1.75%)
     
  • CMC Crypto 200

    1,194.73
    -13.97 (-1.16%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • DOW

    39,375.87
    +67.87 (+0.17%)
     
  • CRUDE OIL

    83.44
    -0.44 (-0.52%)
     
  • GOLD FUTURES

    2,399.80
    +30.40 (+1.28%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     
  • HANG SENG

    17,799.61
    -228.67 (-1.27%)
     
  • DAX

    18,475.45
    +24.97 (+0.14%)
     
  • CAC 40

    7,675.62
    -20.16 (-0.26%)
     

Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study

April 18 (Reuters) - Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Savio D'Souza)